CA
NZ
UK
AU
IND
US
…
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Werewolf Therapeutics Inc is a clinical-stage biotech developing tumor-activated cytokines intended to concentrate immune stimulation in the tumor microenvironment while limiting systemic exposure. Long-term growth may be driven by clinical proof-of-concept, partnerships to enable combinations with approved immunotherapies, and expansion of a platform-enabled oncology pipeline that could address safety limits of systemic cytokines.
Principal risks are early-stage clinical and technical uncertainty, limited human data, likely need for additional financing, regulatory approval risk, and strong competition in immuno-oncology.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M |
| Net income | -60.82M | -70.52M | -37.37M | -51.56M | -49.77M |
| Selling general administrative | 15.85M | 19.05M | 18.67M | 18.70M | 14.82M |
| Selling and marketing expenses | - | - | 1.76M | - | - |
| Gross profit | -1.63M | 0.07M | 18.18M | 16.40M | - |
| Reconciled depreciation | 1.63M | 1.81M | 1.72M | 1.10M | 0.22M |
| Ebit | -55.55M | -65.86M | -34.23M | -57.16M | -50.30M |
| Ebitda | -53.91M | -64.05M | -32.47M | -56.06M | -50.09M |
| Depreciation and amortization | 1.63M | 1.81M | 1.76M | 1.10M | 0.22M |
| Non operating income net other | - | - | - | 2.25M | 0.10M |
| Operating income | -60.68M | -73.59M | -40.50M | -56.06M | -50.09M |
| Other operating expenses | 60.68M | 75.48M | 60.45M | 72.46M | 50.09M |
| Interest expense | 5.27M | 4.66M | 3.14M | 1.10M | 0.22M |
| Interest income | 3.11M | 6.67M | 4.49M | 1.91M | 0.10M |
| Net interest income | -2.17M | 2.02M | 4.49M | 1.91M | 0.10M |
| Income tax expense | - | - | 1.60M | -2.25M | -0.22M |
| Total revenue | 0.00M | 1.89M | 19.94M | 16.40M | 0.00M |
| Total operating expenses | 59.04M | 73.67M | 58.68M | 72.46M | 50.09M |
| Cost of revenue | 1.63M | 1.81M | 1.76M | - | - |
| Total other income expense net | -0.14M | 3.08M | 3.13M | 2.25M | 0.10M |
| Net income from continuing ops | -60.82M | -70.52M | -37.30M | -53.81M | -49.98M |
| Net income applicable to common shares | - | - | - | -53.81M | 101.96M |
| Preferred stock and other adjustments | - | - | - | - | 151.94M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 69.40M | 126.93M | 174.83M | 160.25M | 179.25M |
| Other current assets | 0.64M | 2.07M | 2.68M | 3.96M | 3.54M |
| Total liab | 44.59M | 53.54M | 63.46M | 37.91M | 26.46M |
| Total stockholder equity | 24.80M | 73.39M | 111.37M | 122.34M | 152.79M |
| Other current liab | 33.64M | 10.59M | 8.86M | 14.15M | 8.77M |
| Common stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -475.41M | -414.59M | -344.07M | -306.70M | -252.90M |
| Other assets | - | - | 0.00M | 10.88M | 1.86M |
| Cash | 57.95M | 111.00M | 134.34M | 129.31M | 157.53M |
| Total current liabilities | 36.15M | 15.18M | 19.38M | 23.99M | 11.87M |
| Current deferred revenue | - | - | 0.91M | 6.53M | - |
| Net debt | -48.52M | -73.91M | -82.42M | -114.63M | -141.87M |
| Short term debt | 1.75M | 1.56M | 8.28M | 2.08M | 1.07M |
| Short long term debt | 28.24M | - | 6.67M | - | - |
| Short long term debt total | 9.44M | 37.09M | 51.92M | 14.68M | 15.66M |
| Other stockholder equity | 500.21M | 487.97M | 455.44M | 429.04M | 405.68M |
| Property plant equipment | - | - | - | 8.99M | 16.32M |
| Total current assets | 58.59M | 113.07M | 138.37M | 140.20M | 161.07M |
| Net tangible assets | - | - | - | 122.34M | 152.79M |
| Net receivables | - | - | 1.35M | 6.93M | - |
| Long term debt | - | 26.09M | 32.66M | - | - |
| Accounts payable | 0.75M | 3.04M | 1.34M | 1.22M | 2.04M |
| Accumulated other comprehensive income | - | - | - | - | -179.25M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -306.70M | -252.90M |
| Non currrent assets other | 0.01M | 1.54M | 0.59M | 2.59M | 1.86M |
| Non current assets total | 10.81M | 13.86M | 36.46M | 20.05M | 18.18M |
| Capital lease obligations | 9.44M | 10.99M | 12.60M | 14.68M | 15.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.25M | -1.09M | -3.61M | -0.50M |
| Change to liabilities | - | - | - | 3.05M | 1.01M |
| Total cashflows from investing activities | - | -0.25M | -0.77M | -3.61M | -0.50M |
| Net borrowings | 0.00M | -10.00M | 40.00M | -0.09M | - |
| Total cash from financing activities | 6.03M | 13.08M | 58.43M | 15.91M | 109.43M |
| Change to operating activities | - | - | - | - | 1.27M |
| Net income | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M |
| Change in cash | -54.26M | -43.36M | 25.05M | -28.30M | 66.05M |
| Begin period cash flow | 112.22M | 155.58M | 130.53M | 158.83M | 92.78M |
| End period cash flow | 57.95M | 112.22M | 155.58M | 130.53M | 158.83M |
| Total cash from operating activities | -60.29M | -56.19M | -32.61M | -40.60M | -42.88M |
| Issuance of capital stock | 5.94M | 23.58M | 10.88M | 16.19M | 111.60M |
| Depreciation | 1.63M | 1.81M | 1.76M | 1.10M | 0.22M |
| Change to account receivables | - | 1.35M | 5.58M | - | - |
| Sale purchase of stock | - | - | - | 15.99M | 109.43M |
| Other cashflows from financing activities | 6.03M | -0.50M | 0.10M | -0.28M | -2.17M |
| Change to netincome | - | - | - | 7.41M | 4.61M |
| Capital expenditures | 0.00M | 0.25M | 0.77M | 3.61M | 0.50M |
| Change receivables | - | - | - | -6.93M | - |
| Cash flows other operating | - | - | - | 8.38M | -3.44M |
| Cash and cash equivalents changes | - | - | - | -28.30M | 66.05M |
| Change in working capital | -8.21M | 2.53M | -5.89M | 2.54M | 2.28M |
| Stock based compensation | 6.25M | 8.83M | 8.01M | 7.40M | 4.09M |
| Other non cash items | 0.86M | 1.16M | 0.88M | 2.17M | 0.52M |
| Free cash flow | -60.29M | -56.44M | -33.38M | -44.21M | -43.37M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HOWL Werewolf Therapeutics Inc |
0.01 0.74% |
1.00 | - | - | 2.27 | 2.86 | 1.17 | 0.57 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Daniel J. Hicklin Ph.D. | Founder, CEO, Pres, Sec. & Director | 1964 |
| Mr. Timothy W. Trost CPA | CFO, Treasurer & Assistant Sec. | 1958 |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer | NA |
| Dr. Reid Leonard Ph.D. | Chief Operating Officer | 1959 |
| Dr. Cynthia Seidel-Dugan Ph.D. | Chief Scientific Officer | 1959 |
| Dr. Randi Isaacs M.D. | Chief Medical Officer | 1956 |
| Ms. Ellen A. Lubman M.B.A. | Chief Bus. Officer | 1976 |
| Dr. Daniel J. Hicklin Ph.D. | Founder, CEO, President, Secretary & Director | 1964 |
| Mr. Timothy W. Trost CPA | CFO, Treasurer & Assistant Secretary | 1958 |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer | 1959 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...